{"analyses":[{"ciLowerLimit":"0.78","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.26","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.9368","paramType":"Hazard Ratio (HR)","paramValue":"0.99","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.0","upperLimit":"24.2","value":"22.8"},{"groupId":"OG001","lowerLimit":"18.9","upperLimit":"23.3","value":"21.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"270"},{"groupId":"OG001","value":"135"}],"units":"Participants"}],"description":"Overall survival time is calculated as the time from randomization to death (by any cause) +1 day. Participants who have not died will be censored on the date the participants was last known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Oral rucaparib (monotherapy).\n\nRucaparib: Rucaparib will be administered daily.","id":"OG000","title":"Rucaparib"},{"description":"Oral abiraterone acetate (monotherapy, given in combination with prednisone). Oral enzalutamide (monotherapy). Intravenous docetaxel (monotherapy, given in combination with prednisone or prednisolone).\n\nAbiraterone acetate or Enzalutamide or Docetaxel: Abiraterone acetate and enzalutamide will be administered daily.\n\nDocetaxel will be administered every 3 weeks.","id":"OG001","title":"Abiraterone Acetate or Enzalutamide or Docetaxel"}],"paramType":"MEDIAN","populationDescription":"ITT Population included all randomized participants (participants with BRCA mutated mCRPC and participants with ATM mutated mCRPC).","reportingStatus":"POSTED","timeFrame":"From enrollment to completion of study (up to approximately 7 years)","title":"Overall Survival in Participants With a BRCA or ATM Alteration Combined","type":"SECONDARY","unitOfMeasure":"months"}